Liquid Biopsy in Precision Oncology
Time: 4:30 pm
day: Day 2 PM
Details:
- Successful implementation of Precision Medicine requires accurate and timely biomarker data to inform patient treatment strategies and although tissue remains the gold standard, liquid biopsy testing has many intrinsic advantages
- The US FDA has approved 5 Companion Diagnostic with plasma as the sample type for use in identifying patients eligible for 15 unique precision medicine therapeutics across multiple solid tumor cancers including tumor agnostic and group class approvals and new applications such as molecular residual disease monitoring and early cancer detection are in development Barriers preventing greater use of liquid biopsy in clinical practice and what it will take to overcome them for increased patient benefit will be discussed
